Chinese pharmaceuticals: does sub-national marketisation matter? Evidence of cross-province acquisitions by Guangdong pharmaceutical firms
by Manli Huang; Huiru Zhang; Antonio Angelino
International Journal of Healthcare Technology and Management (IJHTM), Vol. 16, No. 1/2, 2017

Abstract: This article assesses the influence of sub-national marketisation on the equity share choice in mergers and acquisitions. Focusing on domestic acquisitions, we examine the relationship between marketisation of the target firm and the acquirer firm's equity share choice by Guangdong (GD) firms in pharmaceuticals. Our sample consists of 53 domestic acquisitions in China of which acquirers are located in GD province and targets are located all over China. Findings confirm that differences exist in equity share choice based on different sub-national marketisation within China. Sub-national marketisation has significant association with equity share in cross-province acquisitions. An acquirer will more likely opt for partial shares in the acquired firm than full shares when acquiring a firm across provinces.

Online publication date: Sun, 22-Oct-2017

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Healthcare Technology and Management (IJHTM):
Login with your Inderscience username and password:

    Username:        Password:         

Forgotten your password?


Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com